Cargando…

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study

BACKGROUND: This study was designed to assess the long-term safety and tolerability of a new flexible extended regimen of ethinylestradiol (EE) 20 μg/drospirenone (DRSP) 3 mg, which allows management of intracyclic (breakthrough) bleeding [flexible management of intracyclic (breakthrough) bleeding (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klipping, Christine, Duijkers, Ingrid, Fortier, Michel P, Marr, Joachim, Trummer, Dietmar, Elliesen, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353878/ https://www.ncbi.nlm.nih.gov/pubmed/22454004 http://dx.doi.org/10.1136/jfprhc-2011-100214

Ejemplares similares

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study
por: Strowitzki, Thomas, et al.
Publicado: (2012)

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
por: Momoeda, Mikio, et al.
Publicado: (2017)

Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
por: Wiegratz, Inka, et al.
Publicado: (2015)

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People’s Republic of China: a comparison with international studies
por: Marr, Joachim, et al.
Publicado: (2015)

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)
por: Bitzer, Johannes, et al.
Publicado: (2015)

An Oral Contraceptive Containing Estetrol 15 MG and Drospirenone 3 MG Has Limited Effects on Endocrine and Metabolic Parameters
por: Klipping, Christine, et al.
Publicado: (2021)

Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies
por: Elliesen, Jörg, et al.
Publicado: (2016)

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg
por: Bonassi Machado, Rogerio, et al.
Publicado: (2020)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
por: Mathur, Ruchi, et al.
Publicado: (2008)

Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel
por: Klipping, Christine, et al.
Publicado: (2012)

The Effect of Estetrol/Drospirenone on Ovarian Function Is Similar to a Well-Established Combined Oral Contraceptive: Results From a Phase 2 Study
por: Duijkers, Ingrid J M, et al.
Publicado: (2021)

The Efficacy of the Yasmin[Ethinylestradiol-Drospirenone (0.03/3 mg)] Treatment for Postoperative Abortion: A Protocol of Meta-Analysis
por: Tian, Tian, et al.
Publicado: (2022)

Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey
por: Davis, Kimberly H., et al.
Publicado: (2017)

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
por: Duijkers, Ingrid J.M., et al.
Publicado: (2015)

Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg
por: Palacio-Cardona, John, et al.
Publicado: (2017)

Quality of Life in Japanese Patients with Dysmenorrhea or Endometriosis-Associated Pelvic Pain Treated with Extended Regimen Ethinylestradiol/Drospirenone in a Real-World Setting: A Prospective Observational Study
por: Yoshino, Osamu, et al.
Publicado: (2022)

Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin
por: Sun, Xianchang, et al.
Publicado: (2015)

Effect and safety of drospirenone and ethinylestradiol tablets (II) for dysmenorrhea: A systematic review and meta-analysis
por: Shi, Jinghua, et al.
Publicado: (2022)

Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

Ethinylestradiol(30μg)-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
por: Ilie, Ioana Rada, et al.
Publicado: (2012)

EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation
por: Diefenbach, Konstanze, et al.
Publicado: (2013)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021)

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen
por: Mansour, Diana, et al.
Publicado: (2011)

Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

Comparison of the Effects of Hysteroscopic Cold Broad Sword Play Combined with Estrogen and Progestin Sequential Therapy and Drospirenone and Ethinylestradiol Tablets in Patients with Severe Intrauterine Adhesion
por: Zhou, Liping, et al.
Publicado: (2022)

Drospirenone and mood
por: Zuschmann, Andrew
Publicado: (2022)

Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women
por: Momoeda, Mikio, et al.
Publicado: (2014)

Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
por: Park, Bo Ra, et al.
Publicado: (2017)

Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin
por: Bachmann, Gloria, et al.
Publicado: (2009)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers
por: Melka, Dace, et al.
Publicado: (2020)

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
por: Yoo, Jun-Il, et al.
Publicado: (2017)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

The benefits of estetrol addition to drospirenone for contraception
por: Foidart, Jean Michel, et al.
Publicado: (2023)

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, S., et al.
Publicado: (2020)

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study
por: Grillo, Caterina Maria, et al.
Publicado: (2021)

Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L
por: Rosario, Pedro Weslley, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2l72havb9s1qrmsejphbpn8b8l